Nykode Therapeutics AS (VACBF,NYKD.OL), an Oslo-based clinical-stage biopharmaceutical platform, on Wednesday it reported profit in the second quarter compared with the previous year.
For the second quarter, profit came in at $859 million compared with loss of $7.39 billion in the prior year.
Operating loss narrowed to $6.68 billion from $11.79 billion in the prior year.
However, revenue for the quarter declined to $198 million from $584 million in the previous year.
On Tuesday, Nykode Therapeutics closed trading, 3.89% lesser at NOK 1.7300 on the Oslo Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.